Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STUART HAL ISAACSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1023059169
CMS profile
318175
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$782,978.05

706 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STUART HAL ISAACSON

NPI 1023059169 · CMS profile ID 318175

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STUART HAL ISAACSON, NPI 1023059169, CMS profile ID 318175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STUART HAL ISAACSON, NPI 1023059169, CMS profile ID 318175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STUART HAL ISAACSON, NPI 1023059169, CMS profile ID 318175, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 15; records 601–650 of 706 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023059169?year=2019&recipient=provider&page=13#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

706 matching records · $782,978.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 706 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 601–650 of 706.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
US WorldMeds, LLC $179.0002/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441771 CMS
US WorldMeds, LLC $27.0402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441795 CMS
US WorldMeds, LLC $2.2802/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441801 CMS
US WorldMeds, LLC $29.8802/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441807 CMS
US WorldMeds, LLC $58.6102/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441843 CMS
US WorldMeds, LLC $23.2702/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441869 CMS
US WorldMeds, LLC $125.0002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441743 CMS
US WorldMeds, LLC $179.0002/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441779 CMS
US WorldMeds, LLC $29.3202/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441785 CMS
US WorldMeds, LLC $23.2702/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441860 CMS
Amneal Pharmaceuticals LLC $18.2802/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315729 CMS
Avanir Pharmaceuticals, Inc. $20.0002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653570029 CMS
Neurocrine Biosciences, Inc. $125.0002/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136901 CMS
Neurocrine Biosciences, Inc. $284.3902/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136903 CMS
Neurocrine Biosciences, Inc. $44.5602/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136905 CMS
Neurocrine Biosciences, Inc. $54.9602/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136907 CMS
Neurocrine Biosciences, Inc. $59.4202/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136909 CMS
Neurocrine Biosciences, Inc. $4,000.0002/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136911 CMS
Neurocrine Biosciences, Inc. $42.9202/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136913 CMS
Neurocrine Biosciences, Inc. $4.0002/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136915 CMS
Amneal Pharmaceuticals LLC $3,250.0002/15/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315725 CMS
Amneal Pharmaceuticals LLC $1,625.0002/15/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315727 CMS
Neurocrine Biosciences, Inc. $438.6002/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136897 CMS
Neurocrine Biosciences, Inc. $125.0002/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693136899 CMS
Teva Pharmaceuticals USA, Inc. $124.9902/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882223 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0002/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882177 CMS
Amneal Pharmaceuticals LLC $809.3902/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315723 CMS
Teva Pharmaceuticals USA, Inc. $117.7102/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882229 CMS
Allergan Inc. $500.0002/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670575837 CMS
Amneal Pharmaceuticals LLC $114.3302/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315721 CMS
Teva Pharmaceuticals USA, Inc. $57.0402/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882095 CMS
Teva Pharmaceuticals USA, Inc. $3,030.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882119 CMS
Teva Pharmaceuticals USA, Inc. $301.0102/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882161 CMS
Teva Pharmaceuticals USA, Inc. $194.6702/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882179 CMS
Amneal Pharmaceuticals LLC $329.3602/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315713 CMS
Amneal Pharmaceuticals LLC $2,500.0002/08/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315715 CMS
Amneal Pharmaceuticals LLC $328.2902/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315717 CMS
Amneal Pharmaceuticals LLC $716.9202/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692315719 CMS
Teva Pharmaceuticals USA, Inc. $338.3802/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882129 CMS
Teva Pharmaceuticals USA, Inc. $116.8102/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882247 CMS
US WorldMeds, LLC $424.2202/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441969 CMS
US WorldMeds, LLC $3,500.0002/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441977 CMS
Teva Pharmaceuticals USA, Inc. $4,040.0002/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882139 CMS
US WorldMeds, LLC $3.5102/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441691 CMS
US WorldMeds, LLC $175.8802/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441853 CMS
US WorldMeds, LLC $1,096.2402/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441876 CMS
US WorldMeds, LLC $3,500.0002/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441883 CMS
US WorldMeds, LLC $2,000.0002/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699441889 CMS
Allergan Inc. $15.9302/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670575833 CMS
Teva Pharmaceuticals USA, Inc. $147.6002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697882135 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $782,978.05 706
PY2020 $495,392.36 389
PY2021 $582,149.50 410
PY2022 $486,328.71 418
PY2023 $489,258.09 404
PY2024 $537,440.60 431
PY2025 $572,386.51 365

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $230,485.30 5
PY2025 Principal investigator $1,032,373.98 236
PY2024 Recipient $347.11 2
PY2024 Principal investigator $904,468.05 177
PY2023 Recipient $686.00 2
PY2023 Principal investigator $823,950.67 145
PY2022 Principal investigator $675,119.76 190
PY2021 Recipient $66.46 1
PY2021 Principal investigator $911,612.70 259
PY2020 Recipient $12,182.38 11
PY2020 Principal investigator $816,737.56 247
PY2019 Recipient $69,899.15 17
PY2019 Principal investigator $1,420,795.13 330

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

241 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,780.16 12/31/2025 Non-covered Recipient Entity
RESEARCH INSTITUTE OF THE SOUTHEAST LLC
Multicenter, Evaluator-blinded, Randomized, Controlled Study of the Safety and Effectiveness of JUVEDERM VOLITE XC Injectable Gel for Improvement in Neck Appearance No dispute reported 06/30/2026 1202533213
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson s disease No dispute reported 06/30/2026 1202533215
Principal investigator 1 H. Lundbeck A S $4,116.60 12/19/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251778631
Principal investigator 1 H. Lundbeck A S $7,707.60 12/19/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778661
Principal investigator 1 Ipsen Innovation $5,120.74 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288166
Principal investigator 1 Ipsen Innovation $434.63 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288168
Principal investigator 1 Ipsen Innovation $4,460.96 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288170
Principal investigator 1 Ipsen Innovation $5,120.74 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288172
Principal investigator 1 Ipsen Innovation $4,460.96 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288174
Principal investigator 1 Ipsen Innovation $4,008.53 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288176
Principal investigator 1 Ipsen Innovation $434.63 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288178
Principal investigator 1 Ipsen Innovation $4,460.96 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288180
Principal investigator 1 Ipsen Innovation $5,120.74 12/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288182
Recipient Amneal Pharmaceuticals LLC $3,000.00 12/18/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530701
Principal investigator 1 H. Lundbeck A S $4,840.20 12/11/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251778286
Principal investigator 1 H. Lundbeck A S $4,409.10 12/11/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778366
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $809.00 12/05/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242369009
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $809.00 12/05/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242369011
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $40.45 12/05/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242369033
Principal investigator 1 ABBVIE INC. $3,310.24 12/04/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202527814
Principal investigator 1 ABBVIE INC. $8,119.08 12/04/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202527816
Recipient Amneal Pharmaceuticals LLC $28,000.00 12/04/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530697
Principal investigator 1 H. Lundbeck A S $7,051.50 12/04/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778086
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $500.00 12/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242368515
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $400.00 12/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242368533
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,280.00 12/04/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052701
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,200.00 12/01/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242368261
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,400.00 12/01/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242368263
Principal investigator 1 H. Lundbeck A S $6,814.80 11/26/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777761
Principal investigator 1 ABBVIE INC. $465.00 11/25/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202525272
Recipient Amneal Pharmaceuticals LLC $129,150.04 11/20/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530693
Principal investigator 1 H. Lundbeck A S $1,539.00 11/14/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251777174
Principal investigator 1 H. Lundbeck A S $5,188.40 11/14/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251777231
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,747.44 11/14/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052699
Principal investigator 1 ABBVIE INC. $2,240.00 11/11/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202523741
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,546.42 11/07/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052697
Principal investigator 1 H. Lundbeck A S $8,978.40 11/06/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776550
Principal investigator 1 ABBVIE INC. $14,644.44 11/04/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202520487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $154.38 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.90 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.45 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.90 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.45 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $154.38 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.40 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.45 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.45 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.15 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.40 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.40 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.45 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.15 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.40 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.15 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9.45 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.80 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $154.38 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.80 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.40 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.80 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $248.40 10/29/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184254833
Principal investigator 1 H. Lundbeck A S $2,271.60 10/28/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776336
Principal investigator 1 H. Lundbeck A S $500.00 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775958
Principal investigator 1 H. Lundbeck A S $16,475.00 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775979
Principal investigator 1 H. Lundbeck A S $2,000.00 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775986
Principal investigator 1 H. Lundbeck A S $10,000.00 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775990
Principal investigator 1 H. Lundbeck A S $1,622.70 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251775997
Principal investigator 1 H. Lundbeck A S $65,468.00 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776030
Principal investigator 1 H. Lundbeck A S $3,889.80 10/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251776046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,500.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $555.00 10/22/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) No dispute reported 06/30/2026 1184251742
Principal investigator 1 H. Lundbeck A S $7,185.60 10/16/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775777
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $974.23 10/16/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052695
Principal investigator 1 Roche TCRC, Inc. $10,167.30 10/15/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637123
Principal investigator 1 ABBVIE INC. $8,064.36 10/09/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202514719
Principal investigator 1 ABBVIE INC. $458.45 10/09/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202516471
Principal investigator 1 H. Lundbeck A S $5,564.70 10/09/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251775502
Principal investigator 1 H. Lundbeck A S $7,956.00 10/09/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775524
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,773.21 10/09/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052693
Principal investigator 1 H. Lundbeck A S $2,271.60 10/03/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251775240
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,132.31 10/03/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052691
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $809.00 10/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242359854
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,185.00 10/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242359856
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,950.00 10/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242359858
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,625.00 10/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242359860
Principal investigator 1 H. Lundbeck A S $3,530.70 09/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774971
Principal investigator 1 H. Lundbeck A S $21,534.30 09/23/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251774974
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $974.23 09/23/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052689
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $974.23 09/18/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052687
Principal investigator 1 ABBVIE INC. $1,576.78 09/11/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202510818
Principal investigator 1 H. Lundbeck A S $2,642.40 09/11/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774572
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,444.00 09/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242358684
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,392.00 09/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242358686
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,993.00 09/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242358688
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,455.00 09/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242358690
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $809.00 09/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242358692
Principal investigator 1 H. Lundbeck A S $26,020.80 09/04/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251774253
Principal investigator 1 H. Lundbeck A S $5,564.70 09/04/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251774264
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,773.21 09/04/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052847
Principal investigator 1 ABBVIE INC. $3,317.40 09/03/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202507565
Principal investigator 1 ABBVIE INC. $3,310.24 09/03/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202507567
Principal investigator 1 H. Lundbeck A S $16,046.10 08/26/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251773946
Principal investigator 1 H. Lundbeck A S $5,810.40 08/26/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251773954
Principal investigator 1 H. Lundbeck A S $1,936.80 08/21/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251773755
Principal investigator 1 H. Lundbeck A S $5,810.40 08/14/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251773609
Principal investigator 1 Roche TCRC, Inc. $722.00 08/14/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637115
Principal investigator 1 Roche TCRC, Inc. $1,992.60 08/14/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637119
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,787.62 08/14/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052845
Principal investigator 1 ABBVIE INC. $10,477.75 08/13/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202504489
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,948.46 08/07/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052843
Principal investigator 1 ABBVIE INC. $2,714.30 08/06/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202503597
Principal investigator 1 ABBVIE INC. $15,959.43 08/05/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202502018
Principal investigator 1 H. Lundbeck A S $8,182.80 07/31/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251772891
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $974.23 07/31/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052841
Recipient Amneal Pharmaceuticals LLC $35,167.63 07/23/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530684
Recipient Amneal Pharmaceuticals LLC $35,167.63 07/23/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530689
Principal investigator 1 H. Lundbeck A S $16,801.20 07/17/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251772390
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,104.38 07/17/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052839
Principal investigator 1 H. Lundbeck A S $7,185.60 07/10/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251772030
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,773.21 07/10/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052837
Principal investigator 1 ABBVIE INC. $2,002.41 07/08/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497274
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,950.00 07/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242352770
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,625.00 07/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242352772
Principal investigator 1 UCB SA $4,300.00 07/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658744
Principal investigator 1 H. Lundbeck A S $4,543.20 07/03/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251771705
Principal investigator 1 ABBVIE INC. $3,310.24 07/02/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202495527
Principal investigator 1 ABBVIE INC. $1,500.00 07/02/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202495529
Principal investigator 1 H. Lundbeck A S $2,372.40 06/24/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251771483
Principal investigator 1 H. Lundbeck A S $3,941.00 06/24/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251771560
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,080.77 06/24/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052835
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,258.50 06/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052833
Principal investigator 1 ABBVIE INC. $843.75 06/17/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202491713
Principal investigator 1 ABBVIE INC. $2,400.00 06/17/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202491755
Principal investigator 1 ABBVIE INC. $1,000.00 06/17/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202491757
Principal investigator 1 ABBVIE INC. $1,000.00 06/17/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202491759
Principal investigator 1 Roche TCRC, Inc. $13,542.30 06/13/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,227.69 06/12/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052831
Principal investigator 1 H. Lundbeck A S $8,460.90 06/05/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770836
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,104.38 06/05/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052829
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,444.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348798
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,392.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348800
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,950.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348802
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,625.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348804
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,993.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348806
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,455.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348808
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,185.00 06/04/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242348810
Principal investigator 1 ABBVIE INC. $3,317.40 06/03/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202487631
Principal investigator 1 ABBVIE INC. $4,432.24 06/03/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202489025
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $889.00 06/01/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052827
Principal investigator 1 ABBVIE INC. $543.99 05/28/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202486539
Principal investigator 1 ABBVIE INC. $101.25 05/28/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202486541
Principal investigator 1 ABBVIE INC. $101.25 05/28/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202486543
Principal investigator 1 Roche TCRC, Inc. $304.00 05/28/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637102
Principal investigator 1 H. Lundbeck A S $5,810.40 05/27/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770642
Principal investigator 1 ABBVIE INC. $1,500.00 05/22/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202486021
Principal investigator 1 H. Lundbeck A S $3,238.20 05/22/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770572
Principal investigator 1 Ipsen Innovation $3,785.78 05/19/2025 Non-covered Recipient Entity
Parkinsons Disease And Movement Disorders Center Of Boca Raton
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288164
Principal investigator 1 Genentech, Inc. $53,694.00 05/16/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE & MOVEMENT DISO
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211637070
Principal investigator 1 ABBVIE INC. $8,555.00 05/15/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No dispute reported 06/30/2026 1202485053
Principal investigator 1 H. Lundbeck A S $1,936.80 05/15/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770219
Principal investigator 1 H. Lundbeck A S $2,642.40 05/15/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770323
Principal investigator 1 Roche TCRC, Inc. $250.00 05/15/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637111
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,921.00 05/15/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052825
Principal investigator 1 H. Lundbeck A S $1,936.80 05/08/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770106
Principal investigator 1 H. Lundbeck A S $2,271.60 05/08/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251770127
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $974.23 05/08/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052823
Principal investigator 1 ABBVIE INC. $4,004.82 05/07/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202483235
Principal investigator 1 ABBVIE INC. $561.00 05/06/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202481741
Principal investigator 1 H. Lundbeck A S $1,936.80 05/02/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251770011
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,993.00 05/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242344469
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,455.00 05/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242344471
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,185.00 05/02/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242344473
Principal investigator 1 H. Lundbeck A S $1,936.80 04/22/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769772
Principal investigator 1 H. Lundbeck A S $1,936.80 04/17/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769739
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,132.31 04/15/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052819
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $400.00 04/15/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052821
Principal investigator 1 H. Lundbeck A S $12,952.80 04/10/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769584
Principal investigator 1 H. Lundbeck A S $8,090.10 04/10/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251769588
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 04/10/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052817
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,444.00 04/09/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242340794
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,392.00 04/09/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242340796
Principal investigator 1 ABBVIE INC. $8,637.21 04/03/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202469311
Principal investigator 1 ABBVIE INC. $4,432.24 04/03/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson Disease No dispute reported 06/30/2026 1202469315
Principal investigator 1 H. Lundbeck A S $1,936.80 04/03/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769444
Principal investigator 1 ABBVIE INC. $500.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND M
A GLOBAL REAL WORLD EVIDENCE STUDY ON THE LONG TERM EFFECTIVENESS OF ABBV-951 IN ADVANCED PARKINSONS DISEASE No dispute reported 06/30/2026 1202466521
Principal investigator 1 ABBVIE INC. $500.00 03/27/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT
P22-487 - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202466968
Principal investigator 1 Roche TCRC, Inc. $358.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637074
Principal investigator 1 Roche TCRC, Inc. $365.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637078
Principal investigator 1 Roche TCRC, Inc. $647.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637083
Principal investigator 1 Roche TCRC, Inc. $540.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637088
Principal investigator 1 Roche TCRC, Inc. $875.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637091
Principal investigator 1 Roche TCRC, Inc. $250.00 03/27/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211637098
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $974.23 03/25/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052815
Principal investigator 1 H. Lundbeck A S $5,818.50 03/20/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251768986
Principal investigator 1 H. Lundbeck A S $5,175.00 03/20/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768991
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,653.15 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052793
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,800.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052795
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,678.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052797
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,775.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052799
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,050.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052801
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052803
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $800.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052805
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,000.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052807
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $650.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052809
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,360.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052811
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,570.00 03/19/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052813
Principal investigator 1 H. Lundbeck A S $8,182.80 03/14/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768752
Principal investigator 1 ABBVIE INC. $4,919.07 03/13/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202463822
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,950.00 03/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242334662
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,625.00 03/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242334664
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,455.00 03/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242334728
Principal investigator 1 ABBVIE INC. $2,246.07 03/06/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202459071
Principal investigator 1 H. Lundbeck A S $1,936.80 03/06/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768496
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,653.15 03/06/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052791
Principal investigator 1 Sage Therapeutics, LLC $9,579.36 02/27/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206581010
Principal investigator 1 H. Lundbeck A S $3,873.60 02/20/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251767559
Principal investigator 1 UCB SA $40,945.90 02/20/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246658346
Principal investigator 1 UCB SA $26,761.00 02/19/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246657578
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,993.00 02/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242330275
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $809.00 02/07/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242330277
Principal investigator 1 H. Lundbeck A S $3,873.60 02/06/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251767148
Principal investigator 1 Sage Therapeutics, LLC $12,258.71 02/06/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580426
Principal investigator 1 H. Lundbeck A S $6,246.00 01/29/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766765
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,678.92 01/29/2025 Non-covered Recipient Entity
Parkinson's Disease & Movement Disorders Center of Boca Raton
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244052789
Principal investigator 1 H. Lundbeck A S $75.71 01/27/2025 Non-covered Recipient Individual A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778854
Principal investigator 1 H. Lundbeck A S $99.80 01/27/2025 Non-covered Recipient Individual A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778862
Principal investigator 1 H. Lundbeck A S $145.23 01/27/2025 Non-covered Recipient Individual A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778870
Principal investigator 1 H. Lundbeck A S $208.55 01/27/2025 Non-covered Recipient Individual A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778881
Principal investigator 1 H. Lundbeck A S $315.21 01/27/2025 Non-covered Recipient Individual A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778893
Principal investigator 1 H. Lundbeck A S $928.31 01/27/2025 Non-covered Recipient Individual A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) No dispute reported 06/30/2026 1251778902
Principal investigator 1 H. Lundbeck A S $7,117.20 01/17/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766562
Principal investigator 1 ABBVIE INC. $7,511.61 01/16/2025 Non-covered Recipient Entity
PARKINSON S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202439746
Principal investigator 1 H. Lundbeck A S $4,309.20 01/09/2025 Non-covered Recipient Entity
PARKINSONS DISEASE AND MOVEMENT
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766466
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,444.00 01/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242328468
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,392.00 01/08/2025 Non-covered Recipient Entity
PARKINSON'S DISEASE AND MOVEMENT DISORDERS CENTER OF BOCA RATON INC
ITI-214-202 No dispute reported 06/30/2026 1242328492